Exact Mass: 334.0877

Chlorpromazine-N-oxide

C17H19ClN2OS (334.0907)

Chlorpromazine-N-oxide is a metabolite of chlorpromazine. Chlorpromazine (as chlorpromazine hydrochloride, abbreviated CPZ; marketed in the United States as Thorazine and elsewhere as Largactil) is a typical antipsychotic. First synthesized on December 11, 1950, chlorpromazine was the first drug developed with specific antipsychotic action, and would serve as the prototype for the phenothiazine class of drugs, which later grew to comprise several other agents. (Wikipedia)

19-Hydroxy-8-O-methyltetrangulol

C20H14O5 (334.0841)

hydroxychlorpromazine

C17H19ClN2OS (334.0907)

hydroxychlorpromazine is a metabolite of chlorpromazine. Chlorpromazine (as chlorpromazine hydrochloride, abbreviated CPZ; marketed in the United States as Thorazine and elsewhere as Largactil) is a typical antipsychotic. First synthesized on December 11, 1950, chlorpromazine was the first drug developed with specific antipsychotic action, and would serve as the prototype for the phenothiazine class of drugs, which later grew to comprise several other agents. (Wikipedia)

Progabide

C17H16ClFN2O2 (334.0884)

Progabide is an analog and prodrug of gamma-aminobutyric acid. It is commonly used in the treatment of epilepsy. It has agonistic activity for both the GABAA and GABAB receptors. Progabide has been investigated for many diseases besides epilepsy, including Parkinsons disease, schizophrenia, clinical depression and anxiety disorder with varying success. Progabide is a gamma-aminobutyric acid receptor (GABA) agonist.

Chlorpromazine sulfoxide

C17H19ClN2OS (334.0907)

Fluorescin

C20H14O5 (334.0841)

2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic acid

C19H14N2O4 (334.0954)

SCHEMBL4340672

C20H14O5 (334.0841)

Spiropreussomerin A

C20H14O5 (334.0841)

SCH-53823

C20H14O5 (334.0841)

Palmarumycin JC2

C20H14O5 (334.0841)

(8R)-8-(3-Furanyl)-4,8-dihydro-7-methyl-3H-furo[3,4:3,4]cyclohept[1,2-f]isobenzofuran-3,10(1H)-dione; Isopuberulin

C20H14O5 (334.0841)

Sch 50676

C20H14O5 (334.0841)

Plicadin

C20H14O5 (334.0841)

8-Ethyl-1,6,11-trihydroxytetracene-5,12-dione

C20H14O5 (334.0841)

Sophoracoumestan A

C20H14O5 (334.0841)

palmarumycin CP3

C20H14O5 (334.0841)

SCHEMBL17867419

C20H14O5 (334.0841)

cladospirone F

C20H14O5 (334.0841)

Fluorescin

C20H14O5 (334.0841)

palmarumycin CP17

C20H14O5 (334.0841)

Daibucarboline B

C19H14N2O4 (334.0954)

A natural product found in Neolitsea daibuensis.

CHEMBL564438

C20H14O5 (334.0841)

desoxysalvileucantholide|salvileucalin D

C20H14O5 (334.0841)

(2Z)-2-(4-hydroxybenzylidene)-8-methylfuro[2,3-g] [1]benzoxepine-3,10(2H,7H)-dione|damaurone E

C20H14O5 (334.0841)

salvileucalin C

C20H14O5 (334.0841)

4(S)-hydroxy-2,3-dihydro-2H-spiro[naphthalene-1(4H),2-naphtho[1,8-de][1,3]dioxin]-5,8-dione|palmarumycin CP18

C20H14O5 (334.0841)

(8R)-8-(furan-3-yl)-6,8-dihydro-7-methyl-3H-furo[3,4:3,4]cyclohepta[1,2-f][2]benzofuran-3,10(1H)-dione|dugesin B

C20H14O5 (334.0841)

NSC401077

C19H14N2O4 (334.0954)

4,5-Dehydroisopsoralidin

C20H14O5 (334.0841)

Progabide

C17H16ClFN2O2 (334.0884)

D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents N - Nervous system > N03 - Antiepileptics > N03A - Antiepileptics > N03AG - Fatty acid derivatives D018377 - Neurotransmitter Agents > D018682 - GABA Agents > D018755 - GABA Agonists C78272 - Agent Affecting Nervous System > C264 - Anticonvulsant Agent D002491 - Central Nervous System Agents > D000927 - Anticonvulsants Progabide is a gamma-aminobutyric acid receptor (GABA) agonist.

diflufenzopyr

C15H12F2N4O3 (334.0877)

CONFIDENCE standard compound; INTERNAL_ID 1038; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4268; ORIGINAL_PRECURSOR_SCAN_NO 4265 CONFIDENCE standard compound; INTERNAL_ID 1038; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4282; ORIGINAL_PRECURSOR_SCAN_NO 4280 CONFIDENCE standard compound; INTERNAL_ID 1038; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4253; ORIGINAL_PRECURSOR_SCAN_NO 4249 CONFIDENCE standard compound; INTERNAL_ID 1038; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4267; ORIGINAL_PRECURSOR_SCAN_NO 4264 CONFIDENCE standard compound; INTERNAL_ID 1038; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4297; ORIGINAL_PRECURSOR_SCAN_NO 4294 CONFIDENCE standard compound; INTERNAL_ID 1038; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4294; ORIGINAL_PRECURSOR_SCAN_NO 4292 CONFIDENCE standard compound; INTERNAL_ID 1038; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8586; ORIGINAL_PRECURSOR_SCAN_NO 8584 CONFIDENCE standard compound; INTERNAL_ID 1038; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8595; ORIGINAL_PRECURSOR_SCAN_NO 8591 CONFIDENCE standard compound; INTERNAL_ID 1038; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8618; ORIGINAL_PRECURSOR_SCAN_NO 8614 CONFIDENCE standard compound; INTERNAL_ID 1038; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8648; ORIGINAL_PRECURSOR_SCAN_NO 8644 CONFIDENCE standard compound; INTERNAL_ID 1038; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8673; ORIGINAL_PRECURSOR_SCAN_NO 8670 CONFIDENCE standard compound; INTERNAL_ID 1038; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8633; ORIGINAL_PRECURSOR_SCAN_NO 8630

Oxychlorpromazine

C17H19ClN2OS (334.0907)

7-Hydroxychlorpromazine

C17H19ClN2OS (334.0907)

RG-108

C19H14N2O4 (334.0954)

His-Gly-OH

C14H14N4O6 (334.0913)

Ala-His-OH

C14H14N4O6 (334.0913)

Triflubazam

C17H13F3N2O2 (334.0929)

C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent

Pyrimido[4,5-g]quinazoline-4,9-dione,3,8-dihydro-5,10-dihydroxy-2,7-bis(hydroxymethyl)-3,8-dimethyl-

C14H14N4O6 (334.0913)

1,2,13,14-Tetrachlorotetradecane

C14H26Cl4 (334.0789)

3,3-(Hexafluoroisopropylidene)dianiline

C15H12F6N2 (334.0905)

2,2-Bis(4-aminophenyl)hexafluoropropane

C15H12F6N2 (334.0905)

6-ETHYL-7-HYDROXY-3-PHENYL-2-TRIFLUOROMETHYL-CHROMEN-4-ONE

C18H13F3O3 (334.0817)

1,1,1,3-tetrachlorotetradecane

C14H26Cl4 (334.0789)

2,3,4-Tri-O-acetyl-D-glucuronide methyl ester

C13H18O10 (334.09)

benzyl 2-(4-methylphenyl)sulfonyloxypropanoate

C17H18O5S (334.0875)

5-hydroxy-[1,1:3,1-terphenyl]-4,4-dicarboxylic acid

C20H14O5 (334.0841)

1,3-Bis(4-nitrophenoxy)-2-propanol

C15H14N2O7 (334.0801)

4,4-diamino-2,2-di-(trifluoromethyl)-diphenylmethane

C15H12F6N2 (334.0905)

4-(1-Allyl-7-(trifluoromethyl)-1H-indazol-3-yl)benzene-1,3-diol

C17H13F3N2O2 (334.0929)

Mefuparib hydrochloride

C17H16ClFN2O2 (334.0884)

2,3,4-Tri-O-acetyl-alpha-D-glucuronic Acid Methyl Ester

C13H18O10 (334.09)

Salvileucalin B

C20H14O5 (334.0841)

A diterpenoid with a rearranged neo-clerodane skeleton isolated from Salvia leucantha and has been shown exhibit antineoplastic activity.

8-Hydroxychlorpromazine

C17H19ClN2OS (334.0907)

Phenothiazine, 2-chloro-10-(3-(dimethylamino)propyl)-3-hydroxy-

C17H19ClN2OS (334.0907)

N-Pyridoxyl-2-methylalanine-5-phosphate

C12H19N2O7P (334.093)

gamma-L-glutamyl-(S)-2-carboxypropyl-L-cysteine

C12H18N2O7S-2 (334.0835)

RG108

C19H14N2O4 (334.0954)

N-[(2-fluorophenyl)carbamothioyl]-2-(4-methoxyphenoxy)acetamide

C16H15FN2O3S (334.0787)

2-[3-Phenyl-7-(trifluoromethyl)-1-indazolyl]acetic acid methyl ester

C17H13F3N2O2 (334.0929)

3-(2-chloro-10-oxido-10-phenothiazin-10-iumyl)-N,N-dimethyl-1-propanamine

C17H19ClN2OS (334.0907)

Chlorpromazine N-oxide

C17H19ClN2OS (334.0907)

An organochlorine compound that is chlorpromazine in which the acyclic tertiary amino group has been converted into the corresponding N-oxide.

Hydroxy-O-methyltetrangulol

C20H14O5 (334.0841)

1,4,8,9-tetrahydroxy-1h,2h,12ch-benzo[j]fluoranthen-3-one

C20H14O5 (334.0841)

2,7b-dihydro-1ah-2',4'-dioxaspiro[naphtho[1,2-b]oxirene-3,3'-tricyclo[7.3.1.0⁵,¹³]tridecane]-1'(13'),5',7',9',11'-pentaene-2,7-diol

C20H14O5 (334.0841)

(13r)-13-(furan-3-yl)-11-methyl-4,14-dioxatetracyclo[8.7.0.0²,⁶.0¹²,¹⁶]heptadeca-1(17),2(6),8,10,12(16)-pentaene-5,15-dione

C20H14O5 (334.0841)

(1s,4s,8r,9s)-2',4',11-trioxaspiro[tricyclo[6.2.1.0⁴,⁹]undecane-10,3'-tricyclo[7.3.1.0⁵,¹³]tridecane]-1'(13'),5',6,7',9',11'-hexaene-3,5-dione

C20H14O5 (334.0841)

4-hydroxy-3,4-dihydro-2h-2',4'-dioxaspiro[naphthalene-1,3'-tricyclo[7.3.1.0⁵,¹³]tridecane]-1'(13'),5',7',9',11'-pentaene-5,8-dione

C20H14O5 (334.0841)

13-(furan-3-yl)-11-methyl-4,14-dioxatetracyclo[8.7.0.0²,⁶.0¹²,¹⁶]heptadeca-1(17),2(6),8,10,12(16)-pentaene-5,15-dione

C20H14O5 (334.0841)

palmarumycin cp18

C20H14O5 (334.0841)

7,7a-dihydro-1ah-2',4'-dioxaspiro[naphtho[2,3-b]oxirene-2,3'-tricyclo[7.3.1.0⁵,¹³]tridecane]-1'(13'),5',7',9',11'-pentaene-6,7-diol

C20H14O5 (334.0841)

(13r)-13-(furan-3-yl)-11-methyl-4,14-dioxatetracyclo[8.7.0.0²,⁶.0¹²,¹⁶]heptadeca-1(17),2(6),7,10,12(16)-pentaene-5,15-dione

C20H14O5 (334.0841)

(2s)-2,5-dihydroxy-2,3-dihydro-2',4'-dioxaspiro[naphthalene-1,3'-tricyclo[7.3.1.0⁵,¹³]tridecane]-1'(13'),5',7',9',11'-pentaen-4-one

C20H14O5 (334.0841)

4,6b,9-trihydroxy-1h,2h,7h-benzo[j]fluoranthene-3,8-dione

C20H14O5 (334.0841)

(1as,7r,7as)-7,7a-dihydro-1ah-2',4'-dioxaspiro[naphtho[2,3-b]oxirene-2,3'-tricyclo[7.3.1.0⁵,¹³]tridecane]-1'(13'),5',7',9',11'-pentaene-6,7-diol

C20H14O5 (334.0841)

spiropreussione c

C20H14O5 (334.0841)

2',4',11-trioxaspiro[tricyclo[6.2.1.0⁴,⁹]undecane-10,3'-tricyclo[7.3.1.0⁵,¹³]tridecane]-1'(13'),5',6,7',9',11'-hexaene-3,5-dione

C20H14O5 (334.0841)

7,8-dimethoxy-10-phenyl-3-oxatricyclo[7.3.1.0⁵,¹³]trideca-1(13),5,7,9,11-pentaene-2,4-dione

C20H14O5 (334.0841)

2,5-dihydroxy-2,3-dihydro-2',4'-dioxaspiro[naphthalene-1,3'-tricyclo[7.3.1.0⁵,¹³]tridecane]-1'(13'),5',7',9',11'-pentaen-4-one

C20H14O5 (334.0841)

(1s)-5,8-dihydroxy-1-methyl-14-oxapentacyclo[11.6.1.0²,¹¹.0⁴,⁹.0¹⁶,²⁰]icosa-2,4,6,8,10,13(20),15-heptaene-12,17-dione

C20H14O5 (334.0841)

7,7a-dihydro-1ah-2',4'-dioxaspiro[naphtho[2,3-b]oxirene-2,3'-tricyclo[7.3.1.0⁵,¹³]tridecane]-1'(13'),5',7',9',11'-pentaene-4,7-diol

C20H14O5 (334.0841)

(1s,12cr)-1,4,8,9-tetrahydroxy-1h,2h,12ch-benzo[j]fluoranthen-3-one

C20H14O5 (334.0841)

4-[(1e,3z)-2,4-diisocyanato-4-(4-methoxyphenyl)buta-1,3-dien-1-yl]phenol

C19H14N2O4 (334.0954)

(1s,8r,9s)-2',4',11-trioxaspiro[tricyclo[6.2.1.0⁴,⁹]undecane-10,3'-tricyclo[7.3.1.0⁵,¹³]tridecane]-1'(13'),5',6,7',9',11'-hexaene-3,5-dione

C20H14O5 (334.0841)

daibucarboline

C19H14N2O4 (334.0954)

(6bs)-4,6b,9-trihydroxy-1h,2h,7h-benzo[j]fluoranthene-3,8-dione

C20H14O5 (334.0841)

(1ar,7s,7ar)-7,7a-dihydro-1ah-2',4'-dioxaspiro[naphtho[2,3-b]oxirene-2,3'-tricyclo[7.3.1.0⁵,¹³]tridecane]-1'(13'),5',7',9',11'-pentaene-6,7-diol

C20H14O5 (334.0841)

13-(furan-3-yl)-11-methyl-4,14-dioxatetracyclo[8.7.0.0²,⁶.0¹²,¹⁶]heptadeca-1(17),2(6),7,10,12(16)-pentaene-5,15-dione

C20H14O5 (334.0841)